Paul Tudor Jones’s Standard BioTools LAB Stock Holding History

Paul Tudor Jones’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-85,058	Closed	-$164K	–	2602
2023 Q2	$164K	Sell	85,058 -52,468	-38%	-$104K	﹤0.01%	2258
2023 Q1	$268K	Sell	137,526 -55,111	-29%	-$109K	﹤0.01%	2012
2022 Q4	$225K	Hold	192,637	–	–	﹤0.01%	2073
2022 Q3	$212K	Hold	192,637	–	–	﹤0.01%	2029
2022 Q2	$308K	Buy	192,637 +87,598	+83%	+$217K	0.01%	1550
2022 Q1	$377K	Sell	105,039 -16,209	-13%	-$56K	0.01%	1432
2021 Q4	$475K	Buy	+121,248	New	+$568K	0.01%	1513
2019 Q4	–	Sell	-51,597	Closed	-$239K	–	1275
2019 Q3	$239K	Buy	51,597 +33,292	+182%	+$262K	0.01%	921
2019 Q2	$226K	Buy	+18,305	New	+$233K	0.01%	936
2019 Q1	–	Sell	-48,415	Closed	-$417K	–	1189
2018 Q4	$417K	Buy	+48,415	New	+$377K	0.01%	655
2014 Q1	–	Sell	-11,992	Closed	-$459K	–	1319
2013 Q4	$459K	Buy	+11,992	New	+$353K	0.02%	613

Other funds holding LAB

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

Paul Tudor Jones's LAB Position: Q3 2023 in Review

Paul Tudor Jones sold out of Standard BioTools (LAB) in Q3 2023, closing a stake of 85,058 shares — an estimated $164K sold.

Paul Tudor Jones first reported a position in LAB in Q4 2013 and held it in 11 quarters. The position peaked at $475K in Q4 2021. 72 funds tracked by Wall St. Rank hold LAB as of Q3 2023.

Paul Tudor Jones reported no remaining Standard BioTools position as of Q3 2023 after selling out during the quarter.
Paul Tudor Jones sold 85,058 Standard BioTools shares in Q3 2023, an estimated $164K.
Paul Tudor Jones first reported a position in Standard BioTools in Q4 2013 and held it in 11 quarters.
Paul Tudor Jones's Standard BioTools position peaked at $475K in Q4 2021.
72 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2023.

Based on Tudor Investment Corp's 13F filing for Q3 2023, filed 15 Nov 2023.